1) Annunziato F, Cosmi L, Santarlasci V, et al:Phenotypic and functional features of human Th17 cells. J Exp Med 204:1849-1861, 2007
2) Frazer KA, Ballinger DG, Cox DR, et al:A second generation human haplotype map of over 3.1 million SNPs. Nature 449:851-861, 2007
3) Genome-wide association study of 14,000 cases of seven common diseases and 3,000 shared controls. Nature 447:661-678, 2007
4) Genovese MC, Van den Bosch F, Roberson SA, et al:LY2439821, a humanized anti-interleukin-17 monoclonal antibody, in the treatment of patients with rheumatoid arthritis:A phase I randomized, double-blind, placebo-controlled, proof-of-concept study. Arthritis Rheum 62:929-939, 2010
5) Hirota K, Yoshitomi H, Hashimoto M, et al:Preferential recruitment of CCR6-expressing Th17 cells to inflamed joints via CCL20 in rheumatoid arthritis and its animal model. J Exp Med 204:2803-2812, 2007
6) Kochi Y, Okada Y, Suzuki A, et al:A regulatory variant in CCR6 is associated with rheumatoid arthritis susceptibility. Nat Genet 42:515-519, 2010
7) Korn T, Bettelli E, Oukka M, et al:IL-17 and Th17 cells. Annu Rev Immunol 27:485-517, 2009
8) Papp KA, Langley RG, Lebwohl M, et al:Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis:52-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 2). Lancet 371:1675-1684, 2008
9) Pernis AB:Th17 cells in rheumatoid arthritis and systemic lupus erythematosus. J Intern Med 265:644-652, 2009
10) Schutyser E, Struyf SVan Damme J:The CC chemokine CCL20 and its receptor CCR6. Cytokine Growth Factor Rev 14:409-426, 2003